Symptoms and clinical course for study participants with rheumatic disease and COVID-19, stratified by vaccination status at the time of infection
| All rheumatic disease patients (N=280) | Breakthrough COVID-19 infection (N=116) | Non-breakthrough COVID-19 infection (N=164) | P value | |
| Date of COVID-19 diagnosis, n (%) | <0.0001 | |||
| March 1–June 30, 2020 | 45 (16) | 0 (0) | 45 (27) | |
| July 1, 2020–January 31, 2021 | 97 (35) | 0 (0) | 97 (59) | |
| February 1–June 30, 2021 | 21 (8) | 3 (3) | 18 (11) | |
| July 1–December 16, 2021 | 30 (11) | 29 (25) | 1 (1) | |
| December 17, 2021–July 8, 2022 | 87 (31) | 84 (72) | 3 (2) | |
| COVID-19 symptoms, n (%) | ||||
| Fatigue/malaise | 220 (79) | 93 (80) | 127 (77) | 0.66 |
| Fever | 165 (59) | 66 (57) | 99 (60) | 0.62 |
| Headache | 175 (63) | 71 (61) | 104 (63) | 0.71 |
| Myalgias | 162 (58) | 63 (54) | 99 (60) | 0.33 |
| Nasal congestion or rhinorrhoea | 160 (57) | 85 (73) | 75 (46) | <0.0001 |
| Cough | 146 (52) | 73 (63) | 73 (45) | <0.01 |
| Anosmia | 101 (36) | 25 (22) | 76 (46) | <0.0001 |
| Dysgeusia | 106 (38) | 32 (28) | 74 (45) | <0.01 |
| Sore throat | 124 (44) | 63 (54) | 61 (37) | <0.01 |
| Dyspnoea | 83 (30) | 28 (24) | 55 (34) | 0.11 |
| Chest pain | 59 (21) | 25 (22) | 34 (21) | 0.88 |
| Nausea or vomiting | 44 (16) | 16 (14) | 28 (17) | 0.51 |
| Joint pain | 23 (8) | 5 (4) | 18 (11) | 0.049 |
| New rash, hives or blisters | 17 (6) | 4 (3) | 13 (8) | 0.14 |
| None | 64 (23) | 39 (34) | 25 (15) | <0.01 |
| Acute COVID-19 treatment, n (%) | ||||
| Dexamethasone | 17 (6) | 3 (3) | 14 (9) | 0.04 |
| Remdesivir | 12 (4) | 3 (3) | 9 (5) | 0.37 |
| Monoclonal antibody | 52 (19) | 39 (34) | 13 (8) | <0.0001 |
| Nirmatrelvir/ritonavir | 15 (5) | 14 (12) | 1 (1) | <0.0001 |
| COVID-19 severity, n (%) | <0.01 | |||
| Not hospitalised | 244 (87) | 110 (95) | 134 (81) | |
| Hospitalised with or without supplemental oxygen | 32 (11) | 5 (4) | 27 (16) | |